Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 11/20 | 0.65 |
| ▸ | CXCR3 | P49682 | 2/20 | 0.53 |
| ▸ | PTGES | O14684 | 1/20 | 0.53 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.53 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | APLNR | P35414 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23012376 | 0.85 | TAS2R14 (0.61) | TAS2R14CXCR3PTGESTAS2R8PTGER2 | |
| SCHEMBL29691466 | 0.85 | TAS2R14 (0.61) | TAS2R14CXCR3PTGESTAS2R8PTGER2 | |
| SCHEMBL22866793 | 0.84 | TAS2R14 (0.62) | TAS2R14CXCR3PTGESTAS2R8PTGER2 | |
| SCHEMBL23364591 | 0.83 | TAS2R14 (0.74) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL23012494 | 0.81 | TAS2R14 (0.71) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL29691452 | 0.81 | TAS2R14 (0.71) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL6122252 | 0.80 | TAS2R14 (0.74) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL23364620 | 0.80 | TAS2R14 (0.74) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL1893819 | 0.79 | TAS2R14 (0.72) | TAS2R14CXCR3PTGESTAS2R8CNR1 | |
| SCHEMBL1279440 | 0.79 | TAS2R14 (1.00) | TAS2R14CXCR3PTGESTAS2R8CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2022-12-08 | — | — | US | disclosed |
| EP-4013762-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | Inflazome Limited (IE) | 2022-06-22 | — | — | EP | disclosed |
| CN-114555609-A | Macrocyclic sulfonamide derivatives useful as NLRP3 inhibitors | 英夫拉索姆有限公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2021032588-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389031-A1 | MACROCYCLIC SULFONYLAMIDE DERIVATIVES USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | TAS2R14 2154/4885CXCR3 2199/4885PTGES 2332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.